- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01469884
Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (CONCERVIC)
A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The infection by hepatitis C virus (HCV) is the leading cause of chronic liver disease in renal transplant recipients.
The prevalence of pretransplantation anti-HCV is 11% to 49%. The impact of HCV infection on patient survival after renal transplant remains controversial. Some studies also showed that patients undergoing renal transplantation anti-HCV positive are associated with a reduction in graft and patient survival.Chronic infection of HCV is associated with an increased number of infections.
In HCV positive renal transplant patients have been shown that there is an increase from four to seven times in HCV viremia after transplantation compared to pretransplant.
To prevent viral replication, immunosuppression must be adapted, involving a balance between control of viral replication and rejection.
Biochemically, the NS5A protein has been linked to increased replication of the hepatitis C virus through p70S6K phosphopeptides. Sirolimus as inhibitor of pathway mTOR/p70S6K reduced in vivo phosphorylation of NS5A phosphopeptides and thus viral replication. Moreover, the mTOR protein has been proven in vitron to have a protective role against apoptosis in HCV infected cells (WAGNER et al., 2010).
Wagner et al. (2010) showed a beneficial effect of sirolimus on viral recurrence monitored by transaminases and viral load as well as by histological data. They also reported the improved survival after liver transplantation due to hepatitis C for patients receiving sirolimus rather than calcineurin inhibitor-based regimens.
In the literature there have already been reported good virological control of HCV among liver transplant recipients after conversion to SRL and the reduction of hepatitis C virus recurrence (GALLEGO et al., 2009; BENEDETTOET al., 2010).
Everolimus has shown a potent inhibitor of mTOR and has been widely used as an immunosuppressive agent in kidney transplant, but no reported effects on HCV progression was found in the literature.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brésil, 90020090
- Irmandade da Santa Casa de Misericordia de Porto Alegre
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria
- Age ≥ 18 years at the time of screening;
- Subjects between the first and tenth year after renal transplantation;
- Subjects with positive serology for hepatitis C;
- Subjects receiving calcineurin inhibitor (tacrolimus or cyclosporine) plus mycophenolate sodium or mofetil plus prednisone since the first month post-transplant;
- Subjects with no acute rejection episode in the last 3 month;
- Women of childbearing potential (CBP) with a negative pregnancy test at screening (urine or serum;
- Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception throughout the study. The investigator will determine which contraceptive method more effective and appropriate for each study subject. Acceptable methods of contraception include oral contraceptives, barrier methods (eg, diaphragm or condom with spermicide) and intrauterine devices.
Exclusion criteria:
- Subjects who, in the opinion of the investigator, are not able to complete the study;
- Recipients of multiple organ transplant (i.e., prior or concurrent transplantation of a non-renal allograft;
- Subjects with a calculated GFR < 30ml/min (abbreviated MDRD formula;
- Subjects with Urinary protein/creatinine > 0.5;
- Renal biopsy with score ≥ Banff grade II interstitial fibrosis and tubular atrophy (Banff 2007;
- Subjects with a history of biopsy-proven acute rejection within 12 weeks of enrollment;
- Known or suspected hypersensitivity to inhibitor of mTOR;
- Subjects with a history of primary or recurrent FSGS, membranous glomerulonephritis (MGN) or membranoproliferative glomerulonephritis (MPGN);
- Evidence of any active systemic or localized major infection;
- Use of any investigational drug or treatment up to 4 weeks before enrollment;
- Immunosuppressive therapies other than those described by this protocol;
- Planned systemic treatment with voriconazole, cisapride or ketoconazole that will not be discontinued before randomization;
- Prior treatment with aminoglycosides, amphotericin B, cisplatin or other drugs associated with renal dysfunction that is not discontinued before screening;
- Subjects with a screening total white blood cell count (WBC) ≤ 2000/mm3, hemoglobin ≤ 10g/dL and platelet count ≤ 100000/mm3;
- TGO/AST, TGP/ALT and bilirubins with values three times higher than reference values;
- Fasting triglycerides ≥ 400 mg/dL, fasting total cholesterol ≥ 350 mg/dL or LDL-cholesterol ≥ 160mg/dL despite the use of optimal lipid-lowering therapy;
- History of malignancy within 3 years before enrollment other than adequately treated basal cell or squamous cell carcinoma of the skin;
- Subjects who are known to be human immunodeficiency virus (HIV) positive or hepatitis B positive;
- Chronic hepatic failure.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Certican®
Arm1(conversion):Certican®+mycophenolate+prednisone
|
The conversion will be performed abruptly for all patients.
Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1).
Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
|
Comparateur actif: Tacrolimus or Cyclosporine
Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
|
Trough level should be between 100 and 200ng/ml.
Trough level should be between 5 and 10ng/ml.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change from baseline in viral load of hepatitis C virus at 12 months after randomization.
Délai: Baseline,Months 3, 6, 9 and 12 after randomization
|
HCV viremia will be measured by polymerase chain reaction (PCR)
|
Baseline,Months 3, 6, 9 and 12 after randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Incidence of acute allograft rejection
Délai: Weeks 1, 2, 3, months 1, 3, 6, 9 and 12 after randomization
|
All patients will perform at least 07 protocol visits and should be performed renal biopsy during screening phase and during the follow up if present renal dysfunction or proteinuria.
|
Weeks 1, 2, 3, months 1, 3, 6, 9 and 12 after randomization
|
Incidence of significant infections
Délai: Weeks1, 2, 3 and months 1, 3, 6,9 and 12 after randomization
|
During the study visits the patient will be evaluated by a doctor and it will perform blood tests to assess their clinical conditions.
|
Weeks1, 2, 3 and months 1, 3, 6,9 and 12 after randomization
|
Development of proteinuria
Délai: Months 1, 3, 6, 9 and 12 after randomization
|
Spot urine sample for protein and creatinine will be performed.
|
Months 1, 3, 6, 9 and 12 after randomization
|
Development of malignance
Délai: Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Medical evaluation will be performed during the protocol visits and if necessary biopsy and exams of imaging to confirm any suspected.
|
Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Development of dyslipidemia
Délai: Months 1, 3, 6, 9 and 12 after randomization
|
Lipid levels: total cholesterol, HLD, LDL and triglycerides will be performed.
|
Months 1, 3, 6, 9 and 12 after randomization
|
Development of liver impairment
Délai: Months 1, 3, 6, 9, and 12 after randomization
|
Blood chemistry: TGO/AST, TGP/ALT , GGT and alkaline phosphatase will be performed.
|
Months 1, 3, 6, 9, and 12 after randomization
|
Development of post-transplant diabetes
Délai: Months 1, 3, 6, 9 and 12
|
Blood chemistry: Glucose will be performed.
|
Months 1, 3, 6, 9 and 12
|
Development of hypertension
Délai: Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Vital signs will be performed
|
Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Graft loss survival
Délai: Weeks 1, 2 , 3 and months 1, 3 ,6, 9 and 12 after randomization
|
Graft survival will be evaluated by our team doctor.
|
Weeks 1, 2 , 3 and months 1, 3 ,6, 9 and 12 after randomization
|
Patient survival
Délai: Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Subject survival will be evaluated by our team doctor
|
Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Directeur d'études: MARIANA F RODRIGUES, PHARMACIST, Irmandade da Santa Casa de Misericordia de Porto Alegre
- Directeur d'études: DIEGO GNATTA, PHARMACIST, Irmandade da Santa Casa de Misericordia de Porto Alegre
- Directeur d'études: LARISSA S PACHECO, PHARMACIST, Irmandade da Santa Casa de Misericordia de Porto Alegre
- Directeur d'études: BRUNA D CARDOSO, PHARMACIST, Irmandade da Santa Casa de Misericordia de Porto Alegre
- Directeur d'études: RONIVAN L DAL PRA, PHARMACIST, Irmandade da Santa Casa de Misericordia de Porto Alegre
Publications et liens utiles
Publications générales
- Gallego R, Henriquez F, Oliva E, Camacho R, Hernandez R, Hortal L, Sablon N, Quintana B, Santana R, Gonzalez F, Palop L, Vega N. Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option. Transplant Proc. 2009 Jul-Aug;41(6):2334-6. doi: 10.1016/j.transproceed.2009.06.064.
- Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, Fahrleitner-Pammer A, Stiegler P, Tscheliessnigg KH, Iberer F. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol. 2010 Aug;10(8):990-3. doi: 10.1016/j.intimp.2010.05.006. Epub 2010 May 17.
- Benedetto, F. D.; Sandro, S. D.; Ballarin, R.; Guaraldi, G.; Gerunda, G. E. Rapamycin and HIV Replication in Liver Transplant Recipients. Transplantation, 9, 1040, 2010.
- Boletis JN, Iniotaki-Theodoraki A, Psichogiou M, Stamatiadis DN, Viglis JV, Kostakis A, Stavropoulos-Giokas C. Immune status in renal transplant recipients with hepatitis C virus infection. Transplant Proc. 2002 Dec;34(8):3205-8. doi: 10.1016/s0041-1345(02)03656-4. No abstract available.
- Ingsathit A, Thakkinstian A, Kantachuvesiri S, Sumethkul V. Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. Transplant Proc. 2007 Jun;39(5):1424-8. doi: 10.1016/j.transproceed.2007.02.068.
- Ridruejo E, Cusumano A, Diaz C, Davalos Michel M, Jost L, Jost h L, Soler Pujol G, Mando OG, Vilches A. Hepatitis C virus infection and outcome of renal transplantation. Transplant Proc. 2007 Dec;39(10):3127-30. doi: 10.1016/j.transproceed.2007.04.023.
- Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation. 2001 Jul 27;72(2):241-4. doi: 10.1097/00007890-200107270-00013.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Processus pathologiques
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Syndrome de réponse inflammatoire systémique
- Inflammation
- Maladies du foie
- Infections à Flaviviridae
- Hépatite, virale, humaine
- État septique
- Infections à entérovirus
- Infections à Picornaviridae
- Hépatite
- Hépatite A
- Hépatite C
- Virémie
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Inhibiteurs d'enzymes
- Agents antirhumatismaux
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents dermatologiques
- Agents antifongiques
- Inhibiteurs de la calcineurine
- Tacrolimus
- Évérolimus
- Ciclosporine
- Cyclosporines
Autres numéros d'identification d'étude
- CRAD001
- CRAD001ABR20T (Autre identifiant: NOVARTIS)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .